Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.
Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD). We describe the case of a 15-year-old female patient with adverse reaction to aspirin, chronic rhinosinusitis, and severe asthma. She also experienced chronic idiopathic urticaria worsened by non-steroidal anti-inflammatory drug administration. AERD was diagnosed based on clinical history and symptoms. Given the poor responsiveness to standard therapy for respiratory and cutaneous symptoms, omalizumab was administered for 24 weeks with control of respiratory symptoms and short term improvement of cutaneous symptoms. Pediatr Pulmonol. 2017;52:E26-E28. © 2016 Wiley Periodicals, Inc.
Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Federica
F
Porcaro
Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Antonio
A
Di Marco
Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Renato
R
Cutrera
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D000069444:Omalizumab / Q000627:therapeutic use*; D012120:Respiration Disorders / Q000139:chemically induced* / Q000188:drug therapy; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced* / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000069444:Omalizumab; D001241:Aspirin
AERD; anti-IgE therapy; chronic idiopathic urticaria; pulmonology